Prevnar-13 vaccine failure in a mouse model for vitamin A deficiency |
| |
| Affiliation: | 1. Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA;2. Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN 38163, USA;2. Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY;4. Division of Gastroenterology, University of Kentucky, Lexington, KY;11. Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY;1. Thoracic Oncology Unit, Medical Oncology Department 1, Fondazione IRCCS Istituto Nazionale di Tumori, Milan, Italy;2. Clinical Trial Unit, Istituto di Candiolo, FPO-IRCCS, Turin, Italy;1. Department of Medicine Huddinge, Section of Hematology, Karolinska Institutet, Stockholm, Sweden;2. Department of Pediatrics, Karolinska University Hospital, Stockholm, Sweden;3. Department of Immunobiology, Yale University, New Haven, Connecticut;4. Department of Pathology and Laboratory Medicine, Emory Vaccine Center, Emory University, Atlanta, Georgia;5. Centrum för Allogen Stamcellstransplantation, Karolinska University Hospital, Stockholm, Sweden;6. Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;7. Division of Hematology, Karolinska University Hospital, Stockholm, Sweden;1. Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research & Development on Severe Infectious Disease, Kunming 650118, China;2. National Institutes for Food and Drug Control, Beijing 100050, China |
| |
| Abstract: | Streptococcus pneumoniae (pneumococcus) is responsible for serious pediatric respiratory infections, and kills close to one million children under the age of five each year. Unfortunately, the Prevnar-13 vaccine (PCV-13) that is used to protect children from the serious consequences of pneumococcus infections is not always successful. Given that vitamin A deficiency (VAD) is known to affect children in both developed and developing countries, we asked if VAD could be responsible, at least in part, for PCV-13 vaccine failures. In a mouse model for VAD, we found that PCV-13 failed to elicit binding and neutralizing antibody activities. Unlike vaccinated, vitamin-replete animals, vaccinated VAD animals were not protected from lethal pneumococcus infections. Results suggest that children with VAD may be susceptible to serious pneumococcal infections even after having received the PCV-13 vaccine. |
| |
| Keywords: | Pneumococcus Vitamin A deficiency Antibody neutralization Protection Challenge |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
